Analyst Price Targets — STOK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 9:12 pm | — | Wolfe Research | $40.00 | $36.23 | TheFly | Stoke Therapeutics initiated with an Outperform at Wolfe Research |
| February 5, 2026 9:55 am | Yatin Suneja | Guggenheim | $60.00 | $32.00 | TheFly | Stoke Therapeutics initiated with a Buy at Guggenheim |
| January 12, 2026 2:04 pm | — | Wedbush | $36.00 | $28.14 | TheFly | Stoke Therapeutics price target raised to $36 from $32 at Wedbush |
| January 5, 2026 11:53 am | — | Canaccord Genuity | $36.00 | $30.90 | TheFly | Stoke Therapeutics price target raised to $36 from $28 at Canaccord |
| January 5, 2026 9:23 am | Keay Nakae | Loop Capital Markets | $35.00 | $30.90 | StreetInsider | Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy |
| December 16, 2025 11:49 am | Andrew Fein | H.C. Wainwright | $50.00 | $32.90 | StreetInsider | Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright |
| December 15, 2025 1:44 pm | — | UBS | $50.00 | $32.82 | TheFly | Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright |
| November 5, 2025 2:26 pm | — | Canaccord Genuity | $28.00 | $21.42 | TheFly | Stoke Therapeutics price target raised to $28 from $24 at Canaccord |
| October 10, 2025 11:37 am | — | Needham | $35.00 | $29.90 | TheFly | Stoke Therapeutics price target raised to $35 from $22 at Needham |
| August 18, 2025 11:26 am | Thomas Shrader | BTIG | $28.00 | $18.10 | TheFly | Stoke Therapeutics price target lowered to $28 from $29 at BTIG |
Latest News for STOK
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted…
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will…
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its…
The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026. The sale represented 12.20% of Tzianabos' direct Common Stock holdings, reducing direct ownership to 31,339 shares.
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 36.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,227,723 shares of the company's stock after purchasing an additional 327,451 shares during the quarter. Assenagon Asset Management
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STOK.
U.S. House Trading
No House trades found for STOK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.